Author: News Team

The company has seen strong sales growth and investor interest at Amazon Prima day , held annually on July 11-12. The first half of Prime Day 2023 was Amazon’s biggest sales day ever. All the Prime Day stats are out and they are records. The two-day event saw more than 375 million items sold worldwide with savings of more than $2.5 billion. Amazon claims the first day of the event was Amazon’s biggest sales day in their history. The event was also the biggest Prime Day ever for independent retailers, with some small businesses seeing an 18-fold increase in average daily sales. TikTok played a big role in the success of Prime Day, with more than 400 million video views with the hashtags #primeday, #primeday2023 and #amazonprimeday2023. The number of Prime Day-related views has skyrocketed over the past few years, nearly doubling year-over-year. Google was another who briefly flirted with the idea of competing with Amazon. For a while, Google Shopping had a section called “Buy with Google” that allowed shoppers to browse and buy products directly on Google. While Google Shopping is still alive, Google has reportedly killed off its Buy with Google section, with all results now pointing to merchants’ own websites, preventing the notion of Google as a direct competitor to Amazon.

The company recently released financial results for the second quarter of 2023.

– Amazon’s second quarter was very successful. In the fourth quarter, the company expects even higher revenue growth. The company will focus on cutting costs and investing in new areas such as advertising due to the economic difficulties of high order packaging costs.

– Amazon’s second-quarter earnings topped analysts’ expectations, with revenue rising 11% to $134.4 billion compared with the same quarter a year earlier.

– AWS revenue rose 12% to $22.1 billion, accounting for 70% of Amazon’s operating profit.

– Amazon’s advertising business also grew, with revenues of $10.7 billion in the latest quarter.

– Q3 revenue is estimated to be around USD 138bn to USD 143bn, which corresponds to a growth of 9% to 13%.

These facts have attracted the attention of multinational banking corporations and private equity investors to buy shares of Amazon.com, Inc (NASDAQ-AMZN). The average target price for the short- to medium-term investment horizon has been set at $175.90 per share.

Pfizer Inc. (NYSE-PFE) announced via press release that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (COMIRNATY 2023-2024 formulation) for individuals 12 years of age and older, granting emergency use authorization for individuals 6 months of age through 11 years of age for the monovalent COVID-19 vaccine adapted to the Omicron XBB virus mutation.1 .5. This season’s vaccine is indicated, as a single dose, for most individuals 5 years of age and older. Children younger than 5 years may be eligible for additional doses of this season’s vaccine if they have not already received the three-dose series of COVID-19 vaccines, according to a company press release.

Pfizer Chairman and CEO Albert Bourla said: “This decision comes at a time when COVID-19 cases are on the rise again. Most people 6 months of age or older in the U.S. are now eligible for the COVID-19 vaccine this season, even if they have never been vaccinated against COVID-19 before. We expect this season’s vaccine to be available in the coming days, pending a recommendation from public health officials, so people can ask their doctor if it is possible to get the COVID-19 vaccine just as they do for the annual flu vaccine, which will save time and help prevent serious illness when respiratory viruses are at their peak.”

The company also announced yesterday that it is restarting production at its North Carolina plant, which was hit by a tornado in July of this year. With this good news, the company also warned that supplies of some drugs may not be fully restored until the middle of next year.

Pfizer is currently focusing on acquiring new companies to strengthen its pipeline of future products, such as the $5.4 billion buyout of Global Blood Therapeutics Inc and the $11.6 billion buyout of migraine drug maker Biohaven. Pfizer Inc (NYSE-PFE) also pays regular attractive quarterly dividends to its shareholders. The dividend yield is currently 4.97% p.a. The actual dividend amount has been approved by the company’s board of directors at $0.41 per share. These facts have attracted private investors and multinational investment corporations to buy shares of Pfizer Inc. (NYSE-PFE) in particular, for which the average target price for the short- to medium-term investment horizon has been set at USD 45.33 per share.

Vertex Pharmaceuticals (VRTX:NASDAQ) is an American biopharmaceutical company headquartered in Boston, Massachusetts. It was one of the first biotechnology companies to use an explicit strategy of rational drug design without chemistry. The company has three research facilities, in Sandiego, California, and in Milton Park and Oxfordshire, England. Vertex was founded in 1989 by Joshua Boger and Kevin J. Kinsella to “transform the way we treat serious diseases. Until 2004, the company focused primarily on viral infections, inflammatory, autoimmune diseases and cancer. In 2009, the company had about 1,800 employees. In 2019, there were about 2,500 employees. Since the end of 2011, Vertex has been ranked among the top 15 best performing companies in the Standard & Poor’s 500 . Vertex stock has increased 250% over the same period. In January 2014, Vertex completed its move from Cambridge, Massachusetts to Boston, Massachusetts, and settled into a new $800 million complex. This is located on the waterfront in South Boston. In June 2019, Vertex Pharmaceuticals (VRTX:NASDAQ) announced that it will acquire Exonics Therapeutics for $1 billion and partner with CRISPR Therapeutics to advance its development of treatments for Duchenne disease, a so-called muscular dystrophy, and myotonic dystrophy type 1.

Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) announced that the European Medicines Agency (CHMP) (Committee for Medicinal Products for Human Use ) has adopted a positive opinion on the approval of KAFTRIO ® , for the treatment of cystic fibrosis in children aged 2 to 5 years. The first of these medicines, KALYDECO ® (ivacaftor), was approved in 2012. A new drug, KAFTRIO ®, is currently approved for children aged 1 month and older.

Vertex researchers have also won a breakthrough prize for life science, among others. Chief Scientific Officer and Executive Vice President of Global Research David Altshuler, M.D., Ph.D. said “The research teams led by Paul, Fred and Sabine have discovered the first and only drug that addresses the underlying cause of cystic fibrosis. This remarkable effort required the discovery of three new mechanisms of action, leading to the first disease-modifying therapies that work by restoring the function of a misfolded protein.” “This award recognizes both the dedication and creativity of thousands of researchers, as well as the development, access to patients, and tireless staff who have worked to bring medicines to people with CF around the world.”

The company also recently reported financial results for the second quarter of 2023

 The second quarter of 2023 marked another period of significant progress for the business. Cystic fibrosis drugs are reaching more and more patients around the world than ever before. Vertex Pharmaceuticals (VRTX:NASDAQ) is also moving other programs with clinical trials into the final phase, making rapid progress in the development of additional drugs.

Tržby společnosti Vertex Pharmaceuticals (VRTX:NASDAQ) v porovnání se stejným čtvrtletím předchozího roku vzrostly o 14% na 2,49 miliardy USD. Společnost také zvýšila náklady na výzkum a vývoj z 877 milionu USD na 1,2 miliardy USD. Čistý zisk se meziročně zvýšil o 13% na především díky silnému růstu výnosů.